The global spinal biologics market is projected to grow at a 3.6 percent compound annual growth rate to reach $2.55 billion by 2024, according to a Market Study Report.
Biologics
Here are 13 key players in the global non-metal orthopedic biomaterial market, according to a Markets N Research report.
AlloSource enrolled the first patient in a study of its ProChondrix CR for articular cartilage defect repair.
The FDA cleared Atreon Orthopedics' Rotium Bioresorbable Wick for healing rotator cuff injuries.
Barbara A. Binzak Blumenfeld, PhD, is a shareholder at Buchanan Ingersoll & Rooney. She focuses her practice on the regulation of biologic research, and recently spoke with Becker’s Spine Review about where regenerative medicine is headed.
Advertisement
Regenerative medicine company CollPlant renewed its exclusive distribution agreement with Arthrex for its soft tissue repair product Vergenix STR.
Regenerative medicine company IMAC Holdings has a new brand ambassador in former Chicago Bears coach Mike Ditka.
Structural allograft may be superior to intervertebral cages in anterior cervical discectomy and fusion, according to a study in Spine.
SpinalCyte was issued new patents in the U.S. and Japan.
The International Society for the Advancement of Spine Surgery issued a new bone grafting policy that includes Cerapedics' i-FACTOR Peptide Enhanced Bone Graft.